AU2002347369A1 - Immunotherapeutic methods and systems - Google Patents

Immunotherapeutic methods and systems

Info

Publication number
AU2002347369A1
AU2002347369A1 AU2002347369A AU2002347369A AU2002347369A1 AU 2002347369 A1 AU2002347369 A1 AU 2002347369A1 AU 2002347369 A AU2002347369 A AU 2002347369A AU 2002347369 A AU2002347369 A AU 2002347369A AU 2002347369 A1 AU2002347369 A1 AU 2002347369A1
Authority
AU
Australia
Prior art keywords
methods
polypeptide antigen
peptides
antigen
systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002347369A
Other languages
English (en)
Other versions
AU2002347369A8 (en
Inventor
Mark Larche
Philip William Ledger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niox Healthcare Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23324613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002347369(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of AU2002347369A8 publication Critical patent/AU2002347369A8/xx
Publication of AU2002347369A1 publication Critical patent/AU2002347369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
AU2002347369A 2001-12-05 2002-12-05 Immunotherapeutic methods and systems Abandoned AU2002347369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33838501P 2001-12-05 2001-12-05
US60/338,385 2001-12-05
PCT/GB2002/005548 WO2003047618A2 (en) 2001-12-05 2002-12-05 Immunotherapeutic methods and systems

Publications (2)

Publication Number Publication Date
AU2002347369A8 AU2002347369A8 (en) 2003-06-17
AU2002347369A1 true AU2002347369A1 (en) 2003-06-17

Family

ID=23324613

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002347369A Abandoned AU2002347369A1 (en) 2001-12-05 2002-12-05 Immunotherapeutic methods and systems

Country Status (9)

Country Link
US (2) US20060024334A1 (cg-RX-API-DMAC7.html)
EP (1) EP1453539B1 (cg-RX-API-DMAC7.html)
JP (2) JP4874522B2 (cg-RX-API-DMAC7.html)
AT (1) ATE414534T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002347369A1 (cg-RX-API-DMAC7.html)
CA (1) CA2469078A1 (cg-RX-API-DMAC7.html)
DE (1) DE60229979D1 (cg-RX-API-DMAC7.html)
ES (1) ES2316632T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003047618A2 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229979D1 (cg-RX-API-DMAC7.html) * 2001-12-05 2009-01-02 Circassia Ltd
US7279295B2 (en) * 2002-03-27 2007-10-09 Phadia Ab Allergen
CA2486112A1 (en) * 2002-05-16 2003-11-27 Alk Abello A/S Allergen mutants
GB0307989D0 (en) * 2003-04-07 2003-05-14 Mcewen Lab Ltd Therapeutic composition
CN1852701A (zh) * 2003-09-17 2006-10-25 婴儿保健公司 防止过敏的方法及装置
DE10351471A1 (de) * 2003-11-04 2005-06-09 Ursula Prof. Dr. Wiedermann-Schmidt Polyvalente Allergievakzine
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
CN100374152C (zh) 2005-12-23 2008-03-12 中国农业大学 一种过敏性反应抑制剂
JP2007189920A (ja) * 2006-01-17 2007-08-02 Osaka Prefecture Univ イヌアレルギーに対する予防又は治療作用を有するポリペプチド
JP2007189919A (ja) * 2006-01-17 2007-08-02 Osaka Prefecture Univ イヌアレルギーに対する予防又は治療作用を有するポリペプチド
BRPI0807133A2 (pt) * 2007-01-30 2014-04-15 Alk Abello As Uso de um primeiro alérgeno do grupo 2 de ácaro da poeira domiciliar para tratar alergia a um segundo alérgeno do grupo 2 de ácaro da poeira domiciliar
EP2450372B1 (en) 2007-01-30 2015-04-22 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
AU2013202871B2 (en) * 2007-06-01 2015-10-22 Circassia Limited Vaccine peptide combinations against cat allergy
WO2009022155A2 (en) 2007-08-15 2009-02-19 Circassia Limited Peptide with reduced dimer formation
US8821887B2 (en) * 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
DK2153841T4 (en) 2008-08-15 2016-02-15 Circassia Ltd Vaccine comprising Amb a 1 peptides for use in the treatment of ambrosieallergi
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CN102438643B (zh) 2008-11-30 2015-07-01 免疫桑特公司 用于治疗乳糜泻的组合物和方法
BRPI1008802A2 (pt) 2009-02-05 2016-03-08 Circassia Ltd composição, vetor e formulação farmacêutica para o uso na prevenção ou tratamento de alergia a pólen de grama por tolerização, produto, e, método in vitro para determinar se as células t reconhecem uma composição
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
WO2011106645A1 (en) * 2010-02-26 2011-09-01 Benaroya Research Institute Direct analysis of antigen-specific immune response
WO2011112788A1 (en) * 2010-03-12 2011-09-15 Antigen Laboratories, Inc. Methods of treating allergies with substantially phenol-free carriers
EP3524259B1 (en) * 2010-04-30 2021-10-13 Allovate, LLC Oral strip for allergic desensitization via the vestibular mucosal surface
EP2681555B1 (en) 2011-02-25 2020-04-08 Benaroya Research Institute Detection of an allergic disorder
CA2777431A1 (en) * 2011-05-20 2012-11-20 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
US11421006B2 (en) 2012-05-03 2022-08-23 La Jolla Institute For Allergy And Immunology T cell epitopes from Cockroach and methods of making and using same
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
DK2914286T3 (da) 2012-10-30 2021-11-08 Aravax Pty Ltd Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf
JP2014028820A (ja) * 2013-08-30 2014-02-13 China Agricultural Univ アレルギー抑制剤の組成物及びキットならびにその使用方法
EP3043812A1 (en) 2013-09-10 2016-07-20 Immusant Inc. Dosage of a gluten peptide composition
JP2016537299A (ja) 2013-09-19 2016-12-01 アロヴェイト・エルエルシー 口腔粘膜にアレルゲンを供給するための練り歯磨き
JP7007534B2 (ja) 2013-09-25 2022-01-24 アラヴァックス ピーティーワイ リミテッド 新規免疫療法組成物およびその使用
EA034620B1 (ru) * 2014-03-18 2020-02-27 Апептико Форшунг Унд Энтвиклунг Гмбх Пептидный медикамент в виде сухого порошка
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
AU2015323979A1 (en) 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
US10548974B2 (en) 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
US20160362205A1 (en) * 2015-06-02 2016-12-15 ROCA Medical Ltd. Use of autoinjector for distributing antigens to the public
US10369215B2 (en) 2015-06-02 2019-08-06 ROCA Medical Ltd. Predilution sets for distributing antigens
US20170021010A1 (en) * 2015-07-21 2017-01-26 David Phillip ERSTEIN Allergy preventing dosage controlled food packets
KR102797285B1 (ko) * 2016-03-03 2025-04-18 호유 가부시키가이샤 대두 알레르기의 항원
CN108265059B (zh) * 2016-12-31 2021-01-05 江苏众红生物工程创药研究院有限公司 一种重组粉尘螨2类变应原蛋白及其制备方法与应用
CN108265057B (zh) * 2016-12-31 2019-10-18 江苏众红生物工程创药研究院有限公司 一种重组户尘螨2类变应原蛋白及其制备方法和应用
JP7555788B2 (ja) * 2020-10-30 2024-09-25 アサヒグループホールディングス株式会社 タンパク質の起源種判別方法
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358710A (en) * 1989-12-01 1994-10-25 Alec Sehon Method for the suppression of an immune response
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
AU2238395A (en) * 1994-04-01 1995-10-23 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
EP1044019A1 (en) * 1998-01-09 2000-10-18 Circassia Limited Methods and compositions for desensitisation
DE60229979D1 (cg-RX-API-DMAC7.html) * 2001-12-05 2009-01-02 Circassia Ltd

Also Published As

Publication number Publication date
CA2469078A1 (en) 2003-06-12
WO2003047618A2 (en) 2003-06-12
AU2002347369A8 (en) 2003-06-17
ES2316632T3 (es) 2009-04-16
EP1453539A2 (en) 2004-09-08
US20060024334A1 (en) 2006-02-02
EP1453539B1 (en) 2008-11-19
DE60229979D1 (cg-RX-API-DMAC7.html) 2009-01-02
JP2005518367A (ja) 2005-06-23
ATE414534T1 (de) 2008-12-15
WO2003047618A3 (en) 2004-01-08
JP2009292838A (ja) 2009-12-17
US20110142867A1 (en) 2011-06-16
JP4874522B2 (ja) 2012-02-15

Similar Documents

Publication Publication Date Title
AU2002347369A1 (en) Immunotherapeutic methods and systems
HUP9901109A2 (hu) Immunogén peptidek vakcinálásra és allergia kezelésére
WO2002072636A8 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
WO2005013896A3 (en) Programmed immune responses using a vaccination node
Johnston et al. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine
AU2001295671A1 (en) Pharmaceutical composition for immunisation against aids
EP2502998A3 (en) Recombinant toxin A/ToxinB vaccine against clostridium difficile
MXPA01008612A (es) Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
GB0007150D0 (en) Immunotherapeutic methods and compositions
WO2002098360A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
Wolpert et al. Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells
WO2005067460A3 (en) Epha2 vaccines
SG146662A1 (en) Method
NO20050066L (no) Pegylert T20 polypeptid
GB0102145D0 (en) Substances
AU2003241127A1 (en) MEMBRANE-ANCHORED Beta2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
AU6205998A (en) Encapsulated cells producing antibodies
AU2003245781A1 (en) Mhc class ii peptide epitope of 5t4 antigen
ATE234628T1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
AU1041397A (en) Antigenic protein originating in malassezia
WO2000074716A3 (en) Ige peptides for allergy immunotherapy
WO1995006744A3 (en) Methods of suppressing immune response by gene therapy
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase